title: [Meta-analysis of adjuvant chemotherapy on prognosis for gastric cancer patients after D2 dissection].
abstract: OBJECTIVE
  To evaluate efficacy of adjuvant chemotherapy after D2 dissection on survival for patients with gastric cancer.
  
  
  METHODS
  Randomized clinical trials (RCT) that compared adjuvant chemotherapy after D2 dissection with D2 dissection alone for gastric cancer were searched with Pubmed, Cochrane, Embase and CBM databases. Eligible trials published between 1990 and 2012 were included in the study. The quality of RCTs was assessed by the Jadad scale. Data synthesis and statistical analysis were performed by RevMan 5.1 software.
  
  
  RESULTS
  Eight RCTs with 3633 patients were included in this study. Among them, 1824 patients received adjuvant chemotherapy and 1809 patients didn't. Adjuvant chemotherapy was associated with a significant benefit in terms of overall survival (RR = 0.76, 95% CI: 0.69-0.84), disease free survival (RR = 0.72, 95%CI: 0.66-0.80) and recurrence rate (RR = 0.69, 95% CI: 0.62-0.77).
  
  
  CONCLUSIONS
  Adjuvant chemotherapy was associated with survival benefit for gastric cancer after D2 dissection.
authors: Department of Gastrointestinopancreatic Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.
authors: Guang-gai
authors: GG
authors: Xia
authors: Chang-hua
authors: CH
authors: Zhang
authors: Zhe-wei
authors: ZW
authors: Wei
authors: Ying
authors: Y
authors: Wu
authors: Yu-long
authors: YL
authors: He
mesh_terms: D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000601:surgery; D015996:Survival Rate